 4.7%, matting, skin staining, or pigmentation
in 17.8%, and pain at the site of injection in 25.6%.
Morrison et al327 evaluated the safety of carbon dioxide
in patients undergoing 1% polidocanol foam sclerotherapy
and compared them with a historical control of patients
who had air mixed with the sclerosing agent. The carbon
dioxideâ€“ based foam group had 1